TY - JOUR
T1 - Iliofemoral venous stenoses
T2 - Effectiveness of treatment with metallic endovascular stents
AU - Nazarian, Gwen K.
AU - Bjarnason, Haraldur
AU - Dietz, Charles A
AU - Bernadas, Casandra Anderson
AU - Hunter, David W.
PY - 1996/7
Y1 - 1996/7
N2 - PURPOSE: To assess effectiveness of metallic endovascular stents in treatment of venous stenoses and occlusions. MATERIALS AND METHODS: Stents were placed intravenously in 56 patients (59 stenoses or occlusions) over a 6-year period. Stent sites included the inferior vena cava (n = 10) and common iliac (n = 31), external iliac (n = 46), common femoral (n = 27), and superficial femoral veins (n = 4). Indications for stent placement included stenoses from pelvic malignancy and its treatment; trauma, surgery, or pregnancy; and idiopathic stenoses. Patients underwent anticoagulation therapy for 3-6 months after stent placement. Follow-up was performed with duplex ultrasound. RESULTS: With use of life-table analysis, overall primary and secondary 1-year patency rates were 50% and 81%, respectively. Primary and secondary 4-year patency rates were and 50% and 75%, respectively. Five patients died of primary disease progression within 6 months after stent placement. Major complications occurred in 6.8% of cases. One-year secondary patency rates were statistically significantly lower (P =.05) for patients with malignant disease, although primary patency rates were comparable. Overall sustained decrease in symptoms (P <.0001) was observed 1 year later. CONCLUSION: Endovascular stent placement is a nonsurgical alternative for reestablishment of venous flow and sustained relief of symptoms in patients with malignant or benign pelvic venous disease.
AB - PURPOSE: To assess effectiveness of metallic endovascular stents in treatment of venous stenoses and occlusions. MATERIALS AND METHODS: Stents were placed intravenously in 56 patients (59 stenoses or occlusions) over a 6-year period. Stent sites included the inferior vena cava (n = 10) and common iliac (n = 31), external iliac (n = 46), common femoral (n = 27), and superficial femoral veins (n = 4). Indications for stent placement included stenoses from pelvic malignancy and its treatment; trauma, surgery, or pregnancy; and idiopathic stenoses. Patients underwent anticoagulation therapy for 3-6 months after stent placement. Follow-up was performed with duplex ultrasound. RESULTS: With use of life-table analysis, overall primary and secondary 1-year patency rates were 50% and 81%, respectively. Primary and secondary 4-year patency rates were and 50% and 75%, respectively. Five patients died of primary disease progression within 6 months after stent placement. Major complications occurred in 6.8% of cases. One-year secondary patency rates were statistically significantly lower (P =.05) for patients with malignant disease, although primary patency rates were comparable. Overall sustained decrease in symptoms (P <.0001) was observed 1 year later. CONCLUSION: Endovascular stent placement is a nonsurgical alternative for reestablishment of venous flow and sustained relief of symptoms in patients with malignant or benign pelvic venous disease.
KW - Stents and prostheses
KW - Thrombosis, venous
KW - Veins, abnormalities
KW - Veins, transluminal angioplasty
UR - http://www.scopus.com/inward/record.url?scp=0029950011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029950011&partnerID=8YFLogxK
U2 - 10.1148/radiology.200.1.8657909
DO - 10.1148/radiology.200.1.8657909
M3 - Article
C2 - 8657909
AN - SCOPUS:0029950011
SN - 0033-8419
VL - 200
SP - 193
EP - 199
JO - Radiology
JF - Radiology
IS - 1
ER -